A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
NCT05486065
Completed
This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin. The study will look mainly at how well participant's blood sugar and participant's body weight are controlled when they are taking the study medicine at different doses. Participants will either get semaglutide \[2 milligrams (mg), 8 mg, or 16 mg\] or semaglutide placebo (a dummy medicine). Participants will take the study medicine with an injection pen call... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
10/10/2024
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +71 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
NCT04916470
Completed
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms. Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injec... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Eastern Shore Rsrch Inst, LLC, Fairhope, Alabama +117 locations
Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Register for Updates
Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data
NCT05577728
Completed
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes
NCT05478252
Completed
The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D). Participants will either get the currently available semaglutide or the semaglutide which is produced through a new manufacturing process. Participants need to take one injection of semaglutide once a week, on the same day of every week. Participants will have a total of 11 clinic visits and the study will last for about 35 weeks (approximately 8 months)... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/16/2024
Locations: Velocity Clinical Research San Diego, La Mesa, California +64 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
NCT05227196
Completed
The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in. The participants in group 1 will receive treatment for 22 weeks, group 2 for 21 weeks and group 3 for 20 weeks. The study will last up to 29 to 31 weeks for each participant. This includes a screenin... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/06/2024
Locations: Altasciences Clinical LA, Inc., Cypress, California +2 locations
Conditions: Healthy Volunteers, Type 2 Diabetes
Register for Updates
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
NCT05579977
Terminated
The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Ry... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/09/2024
Locations: Trinity Clinical Research, Centreville, Alabama +89 locations
Conditions: Diabetes Mellitus, Obesity
Register for Updates
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
NCT04982575
Completed
This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone. Before a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective. Participants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: Uni of Alabama at Birmingham, Birmingham, Alabama +17 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Pharmacogenetics of Response to GLP1R Agonists
NCT05071898
Recruiting
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims: 1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated fir... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
06/20/2024
Locations: Amish Research Clinic, Lancaster, Pennsylvania
Conditions: Obesity, Diabetes Type 2
Register for Updates
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
NCT03596450
Completed
The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the p... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/07/2024
Locations: American Clinical Trials, Buena Park, California +121 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
NCT05822609
Recruiting
The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Diabetic Kidney Disease, Type 1 Diabetes
Register for Updates
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
NCT05780905
Recruiting
A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication. Given th... Read More
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
06/04/2024
Locations: University of Washington - Harborview Medical Center, Seattle, Washington
Conditions: Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
Register for Updates
Impact of Semaglutide on CD34+ EPC and Fat Derived MSC
NCT04126603
Completed
The Investigator is trying to ascertain whether an FDA approved medication of T2DM, Semaglutide, can improve the number, function and gene expression of subjects CD34+ endothelial progenitor cells. EPCs are the source of cells protecting the inner lining of blood vessels and improving their survivability will improve cardiovascular outcome as high glucose environment of diabetes are toxic to these EPC Cells. Improve mitochondrial metabolism of Mesenchymal Stem Cell from subcutaneous fatty tissu... Read More
Gender:
ALL
Ages:
Between 20 years and 90 years
Trial Updated:
04/24/2024
Locations: The GW Medical Faculty Associates, Washington, District of Columbia +1 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates